AbbVie Migraine Drug Meets Study Goal
AbbVie announced its migraine treatment reduced perimenstrual migraine days in a late stage study. The drug achieved the main goal by showing greater reduction than placebo over three cycles. It also met key secondary goals measuring overall headache burden and medication use.
Insights:
AbbVie said on Thursday afternoon its atogepant treatment reduced monthly migraine days by an average of 0.8 days compared to placebo in a late-stage study. The drug is already approved in the United States under the brand name Qulipta for adult preventive treatment. The expansion targets perstrual migraine episodes over three consecutive cycles.
